Literature DB >> 9559746

Osseous metaplasia in proliferative vitreoretinopathy.

Y D Yoon1, T M Aaberg, T H Wojno, H E Grossniklaus.   

Abstract

PURPOSE: To report the clinicopathologic features of intraocular osseous production in association with proliferative vitreoretinopathy.
METHOD: The clinical and histopathologic features of two patients with proliferative vitreoretinopathy and intraocular bone formation are reviewed.
RESULTS: Preretinal osseous tissue incorporated in the proliferative vitreoretinopathy was surgically removed in one patient, and osseous tissue was present in the proliferative vitreoretinopathy in the enucleated eye of the other patient.
CONCLUSIONS: Bone formation, presumably from metaplastic retinal pigment epithelium, may be present in proliferative vitreoretinopathy tissue. The intraocular bone is present internal rather than external to the neurosensory retina.

Entities:  

Mesh:

Year:  1998        PMID: 9559746     DOI: 10.1016/s0002-9394(99)80201-3

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  4 in total

1.  Calcification of combined hamartoma of the retina and retinal pigment epithelium over 15 years.

Authors:  Colleen M Cebulla; Harry W Flynn
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-10-23       Impact factor: 3.117

2.  Case Report: Multimodal Imaging in a Rare Case of Morning Glory Disc Anomaly Complicated With Choroidal Ossification.

Authors:  Shuya Wang; Xingrong Wang; Ying Wang; Hongsheng Bi
Journal:  Front Med (Lausanne)       Date:  2022-05-16

3.  Small lymphocytic lymphoma in true trilineage hematopoietic tissue within heterotopic ossification in an enucleated blind painful eye: a case report.

Authors:  Alfredo Borgia; Sofia Manara; Monica Balzarotti; Paolo Vinciguerra; Alessandra Di Maria
Journal:  J Med Case Rep       Date:  2020-07-08

4.  Intraocular ossification. Case report.

Authors:  Ciprian Maftei; Horia Tudor Stanca
Journal:  Rom J Ophthalmol       Date:  2017 Jan-Mar
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.